ContraVir to Present at Two Upcoming Investor Conferences

EDISON, N.J., Feb. 2, 2015 /CNW/ -- ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present live at VirtualInvestorConferences.com, an interactive real-time virtual conference, to be held February 5, 2015, and at the 17^th Annual BIO CEO & Investor Conference, to be held February 9-10, 2015 in New York, NY.

James Sapirstein, Chief Executive Officer, will provide an overview of the Company's business during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend the BIO CEO & Investor Conference. 

Event:		VirtualInvestorConferences.com
Date:		Thursday, February 5, 2015
Time:		10:45 am (Eastern Time)
Link:		http://www.virtualinvestorconferences.com
Event:		17^th Annual BIO CEO & Investor Conference
Date:		Monday, February 9, 2015
Time:		05:00 pm (Eastern Time)
Location:		Waldorf Astoria, New York, NY

The VirtualInvestorConferences.com presentation will be webcast live and remain available for an additional 90 days following the live presentation. To access the webcast, please visit the Investors section of the ContraVir website at www.contravir.com/ctrv/.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus (VZV).  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread^®).  CMX157 is active against HBV and more than 200-fold more potent in vitro versus tenofovir against all major HIV subtypes resistant to current therapies.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  ContraVir intends to develop CMX157 for HBV and HIV in Phase 2 clinical studies. 

About VirtualInvestorConferences.com

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on ContraVir's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir's Form 10-K for the year ended June 30, 2014 and other periodic reports filed with the Securities and Exchange Commission.

SOURCE ContraVir Pharmaceuticals, Inc.

Tiberend Strategic Advisors, Inc. (http://www.tiberend.com), Tirth Patel (investors), [email protected]; [phone]; Claire Sodja (media), [email protected]; [phone]